Pub. Date : 2018 Oct
PMID : 30455994
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In the present study, we review the clinical results of rituximab, which targets B lymphocytes, siltuximab and tocilizumab, which target the IL-6 pathway, bortezomib, which is a selective proteasome inhibitor, and anakinra, which is an interleukin 1 receptor antagonist. | Bortezomib | interleukin 6 | Homo sapiens |